US 11,920,134 B2
Compositions and methods for inhibiting expression of RRM2 genes
John Frederick Boylan, Bedminster, NJ (US); Birgit Bramlage, Meggen (CH); Markus Hossbach, Kulmbach (DE); and John Reidhaar-Olson, New York, NY (US)
Assigned to Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US)
Filed by Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US)
Filed on Apr. 13, 2020, as Appl. No. 16/846,535.
Application 16/846,535 is a continuation of application No. 15/906,054, filed on Feb. 27, 2018, granted, now 10,619,160.
Application 15/906,054 is a continuation of application No. 15/415,415, filed on Jan. 25, 2017, granted, now 9,938,531, issued on Apr. 10, 2018.
Application 15/415,415 is a continuation of application No. 14/578,716, filed on Dec. 22, 2014, abandoned.
Application 14/578,716 is a continuation of application No. 13/275,377, filed on Oct. 18, 2011, granted, now 8,946,176, issued on Feb. 3, 2015.
Claims priority of application No. 10187851 (EP), filed on Oct. 18, 2010.
Prior Publication US 2020/0277610 A1, Sep. 3, 2020
Int. Cl. C12N 15/113 (2010.01); A01K 67/00 (2006.01); A61K 48/00 (2006.01); C12N 9/02 (2006.01)
CPC C12N 15/1137 (2013.01) [A01K 67/00 (2013.01); C12N 9/0093 (2013.01); C12N 15/1135 (2013.01); C12Y 117/04001 (2013.01); A61K 48/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/33 (2013.01); C12N 2310/335 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2310/50 (2013.01); C12N 2310/53 (2013.01)] 21 Claims
 
1. A double-stranded ribonucleic acid molecule for inhibiting the expression of a ribonucleotide reductase M2 (RRM2) gene, wherein the double-stranded ribonucleic acid molecule comprises a sense strand and an antisense strand, wherein the antisense strand and the sense strand are each less than about 30 nucleotides in length, wherein the antisense strand comprises the nucleotide sequence of any of SEQ ID NO: 259, 279, 307, 309, 314, 333, 344, 363 or 395, wherein the sense strand is at least substantially complementary to the antisense strand, and wherein the sense strand and/or the antisense strand comprises at least one modified nucleotide.